ArticleJournal of nanobiotechnology2021
Targeted theranostic photoactivation on atherosclerosis.
Article in Journal of nanobiotechnology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 30 citations in OpenAlex.
- Macrophage-induced immunomodulation in oral tissue repair and regeneration: Recent advances and future perspectives.Journal of advanced research · 2026Review
- Enhancing Tumor Photodynamic Therapy via Molecular Engineering and Functional Modification of Photosensitizers.Molecules (Basel, Switzerland) · 2026Review
- Synergistic photodynamic and chemodynamic therapy using hypoxia-adaptive Ce6@Co nanoparticles for enhanced tumor suppression.International journal of pharmaceutics: X · 2025Article
- Nano-therapeutics targeting the macrophage-based microenvironment in the treatment of atherosclerosis.Journal of translational medicine · 2025Review
- Targeted Theranostic Strategy for Atherosclerotic Plaques Using Intravascular Multimodal Imaging Techniques.Journal of lipid and atherosclerosis · 2025Review
- Pitavastatin-loaded procyanidins self-assembled nanoparticles alleviate advanced atherosclerosisActa pharmaceutica Sinica. B · 2025Article
- Ultrabright difuranfluoreno-dithiophen polymers for enhanced afterglow imaging of atherosclerotic plaques.Science advances · 2025Article
- Macrophage-Targeted Nanomedicine for the Treatment of Atherosclerosis.International journal of nanomedicine · 2025Review
- Review
- The biological applications of near-infrared optical nanomaterials in atherosclerosis.Journal of nanobiotechnology · 2024Review
- Niobium carbide MXenzyme-Driven comprehensive cholesterol regulation for photoacoustic image-guided and anti-inflammatory photothermal ablation in atherosclerosis.Bioactive materials · 2024Article
- Photodynamic Therapy for Atherosclerosis: Past, Present, and Future.Pharmaceutics · 2024Review
- Photodynamic Therapy and Cardiovascular Diseases.International journal of molecular sciences · 2024Review
- Comprehensive view of macrophage autophagy and its application in cardiovascular diseases.Cell proliferation · 2024Review
- Advances of nanoparticle-mediated diagnostic and theranostic strategies for atherosclerosis.Frontiers in bioengineering and biotechnology · 2023Review
- Recent Advances for Dynamic-Based Therapy of Atherosclerosis.International journal of nanomedicine · 2023Review
- Dextran Sulfate Nanocarriers: Design, Strategies and Biomedical Applications.International journal of molecular sciences · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 3 institutions in 1 country.
Funding
Abstract
backgroundPhotoactivation targeting macrophages has emerged as a therapeutic strategy for atherosclerosis, but limited targetable ability of photosensitizers to the lesions hinders its applications. Moreover, the molecular mechanistic insight to its phototherapeutic effects on atheroma is still lacking. Herein, we developed a macrophage targetable near-infrared fluorescence (NIRF) emitting phototheranostic agent by conjugating dextran sulfate (DS) to chlorin e6 (Ce6) and estimated its phototherapeutic feasibility in murine atheroma. Also, the phototherapeutic mechanisms of DS-Ce6 on atherosclerosis were investigated.
resultsThe phototheranostic agent DS-Ce6 efficiently internalized into the activated macrophages and foam cells via scavenger receptor-A (SR-A) mediated endocytosis. Customized serial optical imaging-guided photoactivation of DS-Ce6 by light illumination reduced both atheroma burden and inflammation in murine models. Immuno-fluorescence and -histochemical analyses revealed that the photoactivation of DS-Ce6 produced a prominent increase in macrophage-associated apoptotic bodies 1 week after laser irradiation and induced autophagy with Mer tyrosine-protein kinase expression as early as day 1, indicative of an enhanced efferocytosis in atheroma.
conclusionImaging-guided DS-Ce6 photoactivation was able to in vivo detect inflammatory activity in atheroma as well as to simultaneously reduce both plaque burden and inflammation by harmonic contribution of apoptosis, autophagy, and lesional efferocytosis. These results suggest that macrophage targetable phototheranostic nanoagents will be a promising theranostic strategy for high-risk atheroma.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.